Erratum: Dendritic cells and leishmania infection: Adding layers of complexity to a complex disease (Journal of Immunology Research (2016) 2016 (3967436) DOI: 10.1155/2016/3967436);Dendritic cells and leishmania infection: Adding layers of complexity to a complex disease

Journal of Immunology Research

Volumn 2016, Issue , 2016, Pages

  Feijó, Daniel ^a   Tibúrcio, Rafael ^a,b   Ampuero, Mariana ^a,b   Brodskyn, Cláudia ^a,b,c   Tavares, Natalia ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^c Instituto de Investigacao em Imunologia   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

LEISHMANIA VACCINE; PROTOZOAL VACCINE;

ADAPTIVE IMMUNITY; CELL INTERACTION; DENDRITIC CELL; DISEASE PREDISPOSITION; HUMAN; IMMUNE RESPONSE; LEISHMANIA; LEISHMANIASIS; LEUKOCYTE; MACROPHAGE; NEUTROPHIL; NONHUMAN; REVIEW; SKIN LEISHMANIASIS; SYSTEMS BIOLOGY; ANIMAL; CLASSIFICATION; COMPUTER SIMULATION; IMMUNOLOGY; LEISHMANIASIS, CUTANEOUS; MOUSE; PARASITOLOGY;

ANIMALS; COMPUTER SIMULATION; DENDRITIC CELLS; HUMANS; LEISHMANIA; LEISHMANIASIS, CUTANEOUS; MACROPHAGES; MICE; NEUTROPHILS; PROTOZOAN VACCINES; SYSTEMS BIOLOGY;

EID: 84958580804     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2018/1236737     Document Type: Erratum

References (98)

1. WHO/Leishmaniasis, "Leishmaniasis: Magnitude of the problem," 2014, http://www.who.int/leishmaniasis/burden/magnitude/burden magnitude/en/index.html.
2. S. Saha, S. Mondal, A. Banerjee, J. Ghose, S. Bhowmick, and N. Ali, "Immune responses in kala-azar," The Indian Journal of Medical Research, vol. 123, no. 3, pp. 245-266, 2006.
3. A. Caldas, C. Favali, D. Aquino, et al., "Balance of IL-10 and interferon-plasma levels in human visceral leishmaniasis: implications in the pathogenesis," BMC Infectious Diseases, vol. 5, article 113, 2005.
4. H. Goto and J. A. L. Lindoso, "Current diagnosis and treatment of cutaneous andmucocutaneous leishmaniasis," Expert Review of Anti-Infective Therapy, vol. 8, no. 4, pp. 419-433, 2010.
5. P. J. Guerin, P. Olliaro, S. Sundar, et al., "Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda," The Lancet Infectious Diseases, vol. 2, no. 8, pp. 494-501, 2002.
6. C. Reis e Sousa, "Activation of dendritic cells: translating innate into adaptive immunity," Current Opinion in Immunology, vol. 16, no. 1, pp. 21-25, 2004.
7. H. Moll, "Dendritic cells and host resistance to infection," Cellular Microbiology, vol. 5, no. 8, pp. 493-500, 2003.
8. M. Sundquist, A. Rydstrom, and M. J. Wick, "Immunity to Salmonella from a dendritic point of view," Cellular Microbiology, vol. 6, no. 1, pp. 1-11, 2004.
9. T. B. H. Geijtenbeek, S. J. Van Vliet, A. Engering, B. A. t Hart, and Y. van Kooyk, "Self-and nonself-recognition by C-type lectins on dendritic cells," Annual Review of Immunology, vol. 22, pp. 33-54, 2004.
10. K. Takeda and S. Akira, "Microbial recognition by Toll-like receptors," Journal of Dermatological Science, vol. 34, no. 2, pp. 73-82, 2004.
11. Y.-J. Liu, "IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors," Annual Review of Immunology, vol. 23, pp. 275-306, 2005.
12. K. Shortman and Y.-J. Liu, "Mouse and human dendritic cell subtypes," Nature Reviews Immunology, vol. 2, no. 3, pp. 151-161, 2002.
13. J. Zhang, A. Raper, N. Sugita, et al., "Characterization of Siglec-H as a novel endocytic receptor expressed on murine plasmacytoid dendritic cell precursors," Blood, vol. 107, no. 9, pp. 3600-3608, 2006.
14. M. Merad, P. Sathe, J. Helft, J. Miller, and A. Mortha, "The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting," Annual Review of Immunology, vol. 31, pp. 563-604, 2013.
15. K. Crozat, R. Guiton, V. Contreras, et al., "The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8 + dendritic cells," The Journal of Experimental Medicine, vol. 207, no. 6, pp. 1283-1292, 2010.
16. M. Guilliams, F. Ginhoux, C. Jakubzick, et al., "Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny," Nature Reviews Immunology, vol. 14, no. 8, pp. 571-578, 2014.
17. S. Gurka, E. Hartung, M. Becker, and R. A. Kroczek, "Mouse conventional dendritic cells can be universally classified based on the mutually exclusive expression of XCR1 and SIRP," Frontiers in Immunology, vol. 6, article 35, 2015.
18. M. Haniffa, A. Shin, V. Bigley, et al., "Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells," Immunity, vol. 37, no. 1, pp. 60-73, 2012.
19. S. L. Jongbloed, A. J. Kassianos, K. J. McDonald, et al., "Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens," The Journal of Experimental Medicine, vol. 207, no. 6, pp. 1247-1260, 2010.
20. S. H. Robbins, T. Walzer, D. Dembele, et al., "Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profiling," Genome Biology, vol. 9, no. 1, article R17, 2008.
21. A. Schlitzer, N. McGovern, P. Teo, et al., "IRF4 transcription factor-dependent CD11b+ dendritic cells in human and mouse control mucosal IL-17 cytokine responses," Immunity, vol. 38, no. 5, pp. 970-983, 2013.
22. C. Cheong, I. Matos, J.-H. Choi, et al., "Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209+ dendritic cells for immune T cell areas," Cell, vol. 143, no. 3, pp. 416-429, 2010.
23. C. Langlet, S. Tamoutounour, S. Henri, et al., "CD64 expression distinguishes monocyte-derived and conventional dendritic cells and reveals their distinct role during intramuscular immunization," Journal of Immunology, vol. 188, no. 4, pp. 1751-1760, 2012.
24. S. Tamoutounour, M. Guilliams, F. M. Sanchis, et al., "Origins and functional specialization of macrophages and of conventional and monocyte-derived dendritic cells in mouse skin," Immunity, vol. 39, no. 5, pp. 925-938, 2013.
25. M. Greter, I. Lelios, P. Pelczar, et al., "Stroma-derived interleukin-controls the development andmaintenance of langerhans cells and the maintenance of microglia," Immunity, vol. 37, no. 6, pp. 1050-1060, 2012.
26. J. C. Miller, B. D. Brown, T. Shay, et al., "Deciphering the transcriptional network of the dendritic cell lineage," Nature Immunology, vol. 13, no. 9, pp. 888-899, 2012.
27. M. Merad and M. G. Manz, "Dendritic cell homeostasis," Blood, vol. 113, no. 15, pp. 3418-3427, 2009.
28. P. M. A. Gorak, C. R. Engwerda, and P. M. Kaye, "Dendritic cells, but not macrophages, produce IL-12 immediately following Leishmania donovani infection," European Journal of Immunology, vol. 28, no. 2, pp. 687-695, 1998.
29. B. Leon, M. Lopez-Bravo, and C. Ardavin, "Monocyte-derived dendritic cells formed at the infection site control the induction of protective T helper 1 responses against Leishmania," Immunity, vol. 26, no. 4, pp. 519-531, 2007.
30. E. von Stebut, Y. Belkaid, T. Jakob, D. L. Sacks, and M. C. Udey, "Uptake of Leishmania major amastigotes results in activation and interleukin 12 release from murine skin-derived dendritic cells: implications for the initiation of anti-Leishmania immunity," The Journal of Experimental Medicine, vol. 188, no. 8, pp. 1547-1552, 1998.
31. H. Moll, H. Fuchs, C. Blank, and M. Rollinghoff, "Langerhans cells transport Leishmaniamajor from the infected skin to the draining lymph node for presentation to antigen-specific T cells," European Journal of Immunology, vol. 23, no. 7, pp. 1595-1601, 1993.
32. U. Ritter, A. Meiner, C. Scheidig, and H. Korner, "CD8-and Langerin-negative dendritic cells, but not Langerhans cells, act as principal antigen-presenting cells in leishmaniasis," European Journal of Immunology, vol. 34, no. 6, pp. 1542-1550, 2004.
33. M. P. Lemos, F. Esquivel, P. Scott, and T. M. Laufer, "MHC class II expression restricted to CD8 + and CD11b+ dendritic cells is sufficient for control of Leishmania major," Journal of Experimental Medicine, vol. 199, no. 5, pp. 725-730, 2004.
34. K. Kautz-Neu, M. Noordegraaf, S. Dinges, et al., "Langerhans cells are negative regulators of the anti-Leishmania response," The Journal of Experimental Medicine, vol. 208, no. 5, pp. 885-891, 2011.
35. L. G. Ng, A. Hsu, M. A. Mandell, et al., "Migratory dermal dendritic cells act as rapid sensors of protozoan parasites," PLoS Pathogens, vol. 4, no. 11, Article ID e1000222, 2008.
36. M. Martinez-Lopez, S. Iborra, R. Conde-Garrosa, and D. Sancho, "Batf3-dependent CD103+ dendritic cells are major producers of IL-12 that drive local Th1 immunity against Leishmania major infection in mice," European Journal of Immunology, vol. 45, no. 1, pp. 119-129, 2015.
37. M. A. Marovich, M. A. McDowell, E. K. Thomas, and T. B. Nutman, "IL-12p70 production by Leishmaniamajor-harboring human dendritic cells is a CD40/CD40 ligand-dependent process," Journal of Immunology, vol. 164, no. 11, pp. 5858-5865, 2000.
38. S. Henri, J. Curtis, H. Hochrein, D. Vremec, K. Shortman, and E. Handman, "Hierarchy of susceptibility of dendritic cell subsets to infection by Leishmania major: inverse relationship to interleukin-12 production," Infection and Immunity, vol. 70, no. 7, pp. 3874-3880, 2002.
39. M. Akbari, K. Honma, D. Kimura, et al., "IRF4 in dendritic cells inhibits IL-12 production and controls TH1 immune responses against leishmania major," Journal of Immunology, vol. 192, no. 5, pp. 2271-2279, 2014.
40. K. Suzue, S. Kobayashi, T. Takeuchi, M. Suzuki, and S. Koyasu, "Critical role of dendritic cells in determining the Th1/Th2 balance upon Leishmaniamajor infection," International Immunology, vol. 20, no. 3, pp. 337-343, 2008.
41. M. J. Girard-Madoux, K. Kautz-Neu, B. Lorenz, J. L. Ober-Blobaum, E. von Stebut, and B. E. Clausen, "IL-10 signaling in dendritic cells attenuates anti-Leishmania major immunity without affecting protective memory responses," Journal of Investigative Dermatology, vol. 135, no. 11, pp. 2890-2894, 2015.
42. H. Moll, A. Scharner, and E. Kampgen, "Increased interleukin 4 (IL-4) receptor expression and IL-4-induced decrease in IL-12 production by langerhans cells infectedwith Leishmania major," Infection and Immunity, vol. 70, no. 3, pp. 1627-1630, 2002.
43. T. M. Baldwin, C. Elso, J. Curtis, L. Buckingham, and E. Handman, "The site of Leishmania major infection determines disease severity and immune responses," Infection and Immunity, vol. 71, no. 12, pp. 6830-6834, 2003.
44. D. Ashok and H. Acha-Orbea, "Timing is everything: dendritic cell subsets in murine Leishmania infection," Trends in Parasitology, vol. 30, no. 10, pp. 499-507, 2014.
45. U. Ritter, H. Moll, T. Laskay, et al., "Differential expression of chemokines in patients with localized and diffuse cutaneous American leishmaniasis," The Journal of Infectious Diseases, vol. 173, no. 3, pp. 699-709, 1996.
46. M. B. Xavier, F. T. Silveira, S. Demachki, M. M. R. Ferreira, and J. L. M. do Nascimento, "American tegumentary leishmaniasis: a quantitative analysis of Langerhans cells presents important differences between L. (L. ) amazonensis and Viannia subgenus," Acta Tropica, vol. 95, no. 1, pp. 67-73, 2005.
47. J. Ji, J. Sun, and L. Soong, "Impaired expression of inflammatory cytokines and chemokines at early stages of infection with Leishmania amazonensis," Infection and Immunity, vol. 71, no. 8, pp. 4278-4288, 2003.
48. C. Favali, N. Tavares, J. Clarencio, A. Barral, M. Barral-Netto, and C. Brodskyn, "Leishmania amazonensis infection impairs differentiation and function of human dendritic cells," Journal of Leukocyte Biology, vol. 82, no. 6, pp. 1401-1406, 2007.
49. L. Soong, "Modulation of dendritic cell function by leishmania parasites," Journal of Immunology, vol. 180, no. 7, pp. 4355-4360, 2008.
50. A. K. Carvalho, F. T. Silveira, L. F. D. Passero, C. M. C. Gomes, C. E. P. Corbett, and M. D. Laurenti, "Leishmania (V. ) braziliensis and L. (L. ) amazonensis promote differential expression of dendritic cells and cellular immune response inmurinemodel," Parasite Immunology, vol. 34, no. 8-9, pp. 395-403, 2012.
51. L. Ohl, M. Mohaupt, N. Czeloth, et al., "CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions," Immunity, vol. 21, no. 2, pp. 279-288, 2004.
52. F. Geissmann, S. Gordon, D. A. Hume, A. M. Mowat, and G. J. Randolph, "Unravelling mononuclear phagocyte heterogeneity," Nature Reviews Immunology, vol. 10, no. 6, pp. 453-460, 2010.
53. M. K. Ibrahim, J. L. Barnes, E. Y. Osorio, et al., "Deficiency of lymph node-resident dendritic cells (DCs) and dysregulation of DC chemoattractants in a malnourished mouse model of Leishmania donovani infection," Infection and Immunity, vol. 82, no. 8, pp. 3098-3112, 2014.
54. M. Ato, A. Maroof, S. Zubairi, H. Nakano, T. Kakiuchi, and P. M. Kaye, "Loss of dendritic cell migration and impaired resistance to Leishmania donovani infection in mice deficient in CCL19 and CCL21," The Journal of Immunology, vol. 176, no. 9, pp. 5486-5493, 2006.
55. M. Ato, S. Stager, C. R. Engwerda, and P. M. Kaye, "Defective CCR7 expression on dendritic cells contributes to the development of visceral leishmaniasis," Nature Immunology, vol. 3, no. 12, pp. 1185-1191, 2002.
56. A. C. Stanley, J. E. Dalton, S. H. Rossotti, et al., "VCAM-1 and VLA-4 modulate dendritic cell IL-12p40 production in experimental visceral leishmaniasis," PLoS Pathogens, vol. 4, no. 9, Article ID e1000158, 2008.
57. L. P. Carvalho, P. M. Petritus, A. L. Trochtenberg, et al., "Lymph node hypertrophy following Leishmania major infection is dependent on TLR9," The Journal of Immunology, vol. 188, no. 3, pp. 1394-1401, 2012.
58. A. C. Hsu and P. Scott, "Leishmaniamexicana infection induces impaired lymph node expansion and Th1 cell differentiation despite normal T cell proliferation,"The Journal of Immunology, vol. 179, no. 12, pp. 8200-8207, 2007.
59. P. M. Petritus, D. Manzoni-de-Almeida, C. Gimblet, C. Gonzalez Lombana, and P. Scott, "Leishmania mexicana mexicana induces limited recruitment and activation of monocytes and monocyte-derived dendritic cells early during infection," PLoS Neglected Tropical Diseases, vol. 6, no. 10, Article IDe1858, 2012.
60. M. J. de Veer, J. M. Curtis, T. M. Baldwin, et al., "MyD88 is essential for clearance of Leishmania major: possible role for lipophosphoglycan and Toll-like receptor 2 signaling," European Journal of Immunology, vol. 33, no. 10, pp. 2822-2831, 2003.
61. M. Komai-Koma, D. Li, E. Wang, D. Vaughan, and D. Xu, "Anti-Toll-like receptor 2 and 4 antibodies suppress inflammatory response in mice," Immunology, vol. 143, no. 3, pp. 354-362, 2014.
62. D. A. Vargas-Inchaustegui, W. Tai, L. Xin, A. E. Hogg, D. B. Corry, and L. Soong, "Distinct roles for MyD88 and toll-like receptor 2 during Leishmania braziliensis infection in mice," Infection and Immunity, vol. 77, no. 7, pp. 2948-2956, 2009.
63. J. Liese, U. Schleicher, and C. Bogdan, "TLR9 signaling is essential for the innate NK cell response in murine cutaneous leishmaniasis," European Journal of Immunology, vol. 37, no. 12, pp. 3424-3434, 2007.
64. U. Schleicher, J. Liese, I. Knippertz, et al., "NK cell activation in visceral leishmaniasis requires TLR9, myeloid DCs, and IL-12, but is independent of plasmacytoid DCs," The Journal of Experimental Medicine, vol. 204, no. 4, pp. 893-906, 2007.
65. T. Weinkopff, A. Mariotto, G. Simon, et al., "Role of toll-like receptor 9 signaling in experimental Leishmania braziliensis infection," Infection and Immunity, vol. 81, no. 5, pp. 1575-1584, 2013.
66. L. T. Vogelpoel, D. L. Baeten, E. C. de Jong, and J. den Dunnen, "Control of cytokine production by human fc gamma receptors: implications for pathogen defense and autoimmunity," Frontiers in Immunology, vol. 6, article 79, 2015.
67. N. Wanasen, L. Xin, and L. Soong, "Pathogenic role of B cells and antibodies in murine Leishmania amazonensis infection," International Journal for Parasitology, vol. 38, no. 3-4, pp. 417-429, 2008.
68. A. P. Nigg, S. Zahn, D. Ruckerl, et al., "Dendritic cell-derived IL-12p40 homodimer contributes to susceptibility in cutaneous leishmaniasis in BALB/c mice," The Journal of Immunology, vol. 178, no. 11, pp. 7251-7258, 2007.
69. F. Woelbing, S. L. Kostka, K. Moelle, et al., "Uptake of Leishmania major by dendritic cells is mediated by Fc receptors and facilitates acquisition of protective immunity," The Journal of Experimental Medicine, vol. 203, no. 1, pp. 177-188, 2006.
70. E. Prina, S. Z. Abdi, M. Lebastard, E. Perret, N. Winter, and J.-C. Antoine, "Dendritic cells as host cells for the promastigote and amastigote stages of Leishmania amazonensis: the role of opsonins in parasite uptake and dendritic cell maturation," Journal of Cell Science, vol. 117, no. 2, pp. 315-325, 2004.
71. C. L. Bennett, A. Misslitz, L. Colledge, T. Aebischer, and C. C. Blackburn, "Silent infection of bone marrow-derived dendritic cells by Leishmania mexicana amastigotes," European Journal of Immunology, vol. 31, no. 3, pp. 876-883, 2001.
72. M. A. McDowell, M. Marovich, R. Lira, M. Braun, and D. Sacks, "Leishmania priming of human dendritic cells for CD40 ligand-induced interleukin-12p70 secretion is strain and species dependent," Infection and Immunity, vol. 70, no. 8, pp. 3994-4001, 2002.
73. M. X. Hernandez Sanabria, D. A. Vargas-Inchaustegui, L. Xin, and L. Soong, "Role of natural killer cells in modulating dendritic cell responses to Leishmania amazonensis infection," Infection and Immunity, vol. 76, no. 11, pp. 5100-5109, 2008.
74. K. A. Remer, B. Roeger, C. Hambrecht, and H. Moll, "Natural killer cells support the induction of protective immunity during dendritic cell-mediated vaccination against Leishmania major," Immunology, vol. 131, no. 4, pp. 570-582, 2010.
75. F. L. Ribeiro-Gomes, N. C. Peters, A. Debrabant, and D. L. Sacks, "Efficient capture of infected neutrophils by dendritic cells in the skin inhibits the early anti-leishmania response," PLoS Pathogens, vol. 8, no. 2, Article ID e1002536, 2012.
76. B. P. Hurrell, S. Schuster, E. Grun, et al., "Rapid sequestration of Leishmania mexicana by neutrophils contributes to the development of chronic lesion," PLoS Pathogens, vol. 11, no. 5, Article ID e1004929, 2015.
77. I. Matos, O. Mizenina, A. Lubkin, R. M. Steinman, and J. Idoyaga, "Targeting antigens to dendritic cells in vivo induces protectiveimmunity," PLoSONE, vol. 8, no. 6, Article IDe67453, 2013.
78. L. A. Dillon, K. Okrah, V. K. Hughitt, et al., "Transcriptomic profiling of gene expression and RNA processing during Leishmaniamajor differentiation," Nucleic Acids Research, vol. 43, no. 14, pp. 6799-6813, 2015.
79. M. Fiebig, S. Kelly, E. Gluenz, and P. J. Myler, "Comparative life cycle transcriptomics revises Leishmania mexicana genome annotation and links a chromosome duplication with parasitism of vertebrates," PLoS Pathogens, vol. 11, no. 10, Article ID e1005186, 2015.
80. C. S. Peacock, K. Seeger, D. Harris, et al., "Comparative genomic analysis of three Leishmania species that cause diverse human disease," Nature Genetics, vol. 39, no. 7, pp. 839-847, 2007.
81. D. A. Tschoeke, G. L. Nunes, R. Jardimet al., "The comparative genomics and phylogenomics of Leishmania amazonensis parasite," Evolutionary Bioinformatics, vol. 10, pp. 131-153, 2014.
82. E. V. Alves-Ferreira, J. S. Toledo, A. H. De Oliveira, et al., "Differential gene expression and infection profiles of cutaneous and mucosal Leishmania braziliensis isolates from the same patient," PLoS Neglected Tropical Diseases, vol. 9, no. 9, Article ID e0004018, 2015.
83. L. H. Hartwell, J. J. Hopfield, S. Leibler, and A. W. Murray, "From molecular to modular cell biology," Nature, vol. 402, no. 6761, supplement, pp. C47-C52, 1999.
84. H. Kitano, "Systems biology: a brief overview," Science, vol. 295, no. 5560, pp. 1662-1664, 2002.
85. D. Gaucher, R. Therrien, N. Kettaf, et al., "Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses," The Journal of Experimental Medicine, vol. 205, no. 13, pp. 3119-3131, 2008.
86. T. D. Querec, R. S. Akondy, E. K. Lee, et al., "Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans," Nature Immunology, vol. 10, no. 1, pp. 116-125, 2009.
87. C. J. Blohmke, D. O'Connor, and A. J. Pollard, "The use of systems biology and immunological big data to guide vaccine development," Genome Medicine, vol. 7, no. 1, article 114, 2015.
88. J. B. Gutierrez, M. R. Galinski, S. Cantrell, and E. O. Voit, "From within host dynamics to the epidemiology of infectious disease: scientific overview and challenges,"Mathematical Biosciences B, vol. 270, pp. 143-155, 2015.
89. D. E. Zak and A. Aderem, "Systems integration of innate and adaptive immunity," Vaccine, vol. 33, no. 40, pp. 5241-5248, 2015.
90. A. K. Subudhi, P. A. Boopathi, I. Pandey, et al., "Disease specific modules and hub genes for intervention strategies: a coexpression network based approach for Plasmodium falciparum clinical isolates," Infection, Genetics and Evolution, vol. 35, pp. 96-108, 2015.
91. L. Albergante, J. Timmis, L. Beattie, and P. M. Kaye, "A Petri netmodel of granulomatous inflammation: implications for IL mediated control of Leishmania donovani infection," PLoS Computational Biology, vol. 9, no. 11, Article ID e1003334, 2013.
92. D. C. Torres, M. Ribeiro-Alves, G. A. S. Romero, A. M. R. Davila, and E. Cupolillo, "Assessment of drug resistance related genes as candidate markers for treatment outcome prediction of cutaneous leishmaniasis in Brazil," Acta Tropica, vol. 126, no. 2, pp. 132-141, 2013.
93. G. Bocharov, R. Zust, L. Cervantes-Barragan, et al., "A systems immunology approach to plasmacytoid dendritic cell function in cytopathic virus infections," PLoS Pathogens, vol. 6, no. 7, Article ID e1001017, pp. 1-15, 2010.
94. D. Cavalieri, D. Rivero, L. Beltrame, et al., "DC-ATLAS: a systems biology resource to dissect receptor specific signal transduction in dendritic cells," Immunome Research, vol. 6, no. 1, article 10, 2010.
95. S. Patil, H. Pincas, J. Seto, G. Nudelman, I. Nudelman, and S. C. Sealfon, "Signaling network of dendritic cells in response to pathogens: a community-input supported knowledgebase," BMC Systems Biology, vol. 4, article 137, 2010.
96. P. Tsagozis, E. Karagouni, and E. Dotsika, "Dendritic cells pulsed with peptides of gp63 induce differential protection against experimental cutaneous leishmaniasis," International Journal of Immunopathology and Pharmacology, vol. 17, no. 3, pp. 343-352, 2004.
97. A. Ives, C. Ronet, F. Prevel, et al., "Leishmania RNA virus controls the severity of mucocutaneous leishmaniasis," Science, vol. 331, no. 6018, pp. 775-778, 2011.
98. D. R. Flower, I. K. Macdonald, K. Ramakrishnan, M. N. Davies, and I. A. Doytchinova, "Computer aided selection of candidate vaccine antigens," Immunome Research, vol. 6, supplement 2, article S1, 2010.